Long-term viral suppression ( hepatitis B virus DNA < 400 copies/ml ) was maintained at week 168 in 84 % and 82 % of patients receiving either emtricitabine/tenofovir combination or tenofovir monotherapy , respectively ( non-completer equal to failure analysis ) .